Merck & Co. said on November 26 updated data from the company’s study of the experimental COVID-19 pill molnupiravir showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.
AstraZeneca is examining the impact of a new coronavirus variant that is spreading rapidly in South Africa on the company’s vaccine and antibody cocktail, and is hopeful that the combination drug would retain efficacy.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened during 2021. And there are many! The accomplishments, opportunities and possibilities the scientific community has brought to bear, providing a way out of the COVID-19 pandemic and hope for the future of meaningful therapies for several challenging diseases, deserve a major shout-out.
A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.
The U.S. Food and Drug Administration greenlit Aadi Bioscience’s Fyarro for treating a rare and aggressive form of cancer that disproportionately affects women.
The U.S. Food and Drug Administration approved Merck’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) for adjuvant treatment of renal cell carcinoma (RCC) patients at intermediate-high or high risk of recurrence after nephrectomy or following nephrectomy and resection of metastatic lesions.
Johnson & Johnson expects to file for approval of 14 new drugs by 2025, and projected average peak sales of $4 billion a year for each, a top J&J scientist said ahead of a strategy review of the company’s pharmaceuticals unit on November 18.
The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative trend vote on the Marketing Authorization Application for Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab).
As Biogen continues to struggle with the fallout from the controversial approval of the Alzheimer’s drug Aduhelm, the company’s head of research and development will step down at the end of 2021.
The European Commission (EC) granted marketing authorization for Biogen Inc.’s Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).